L
Lars Petter Jordheim
Researcher at Claude Bernard University Lyon 1
Publications - 112
Citations - 3386
Lars Petter Jordheim is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Nucleoside & Cancer. The author has an hindex of 25, co-authored 101 publications receiving 2858 citations. Previous affiliations of Lars Petter Jordheim include Lyon College & International Agency for Research on Cancer.
Papers
More filters
Journal ArticleDOI
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
TL;DR: New nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects are reviewed.
Journal ArticleDOI
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphaël Maréchal,Jean-Baptiste Bachet,John R. Mackey,Cécile Dalban,Pieter Demetter,Kathryn Graham,Anne Couvelard,Magali Svrcek,Armelle Bardier–Dupas,Pascal Hammel,Alain Sauvanet,Christophe Louvet,François Paye,Philippe Rougier,Christophe Penna,Thierry André,Charles Dumontet,Carol E. Cass,Lars Petter Jordheim,Eva Matera,Jean Closset,Isabelle Salmon,Jacques Devière,Jean-François Emile,Jean-Luc Van Laethem +24 more
TL;DR: On multivariate analysis of this population, hENT1 and dCK retained independent predictive values, and those patients with high levels of each protein had the longest survival times following adjuvant therapy with gemcitabine.
Journal ArticleDOI
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
Lars Petter Jordheim,Lars Petter Jordheim,Pascal Sève,Pascal Sève,Olivier Tredan,Charles Dumontet,Charles Dumontet +6 more
TL;DR: Preclinical and clinical studies of RRM1 assessment are reviewed and the further steps in the development of this clinically pertinent biomarker are discussed.
Journal ArticleDOI
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
Chloé Grasselly,Morgane Denis,Aurore Bourguignon,Nolan Talhi,Doriane Mathe,Anne Tourette,Laurent Serre,Lars Petter Jordheim,Eva Matera,Charles Dumontet +9 more
TL;DR: The results show that the combination of cytotoxic chemotherapy with ICIs may result in enhanced, similar or reduced antitumor activity, in a model- and regimen-dependent fashion.
Journal ArticleDOI
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues
TL;DR: An update on changes in gene products involved in the metabolic pathway of deoxynucleoside analogues, such as membrane transporters, kinases, deaminases and 5'-nucleotidases is provided.